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Can baseline ultrasound results help to
predict failure to achieve DAS28 remission
after 1 year of tight control treatment in
early RA patients?
D. F. Ten Cate1*, J. W. G. Jacobs2, W. A. A. Swen3, J. M. W. Hazes1, M. H. de Jager4, N. M. Basoski5, C. J. Haagsma6,
J. J. Luime1† and A. H. Gerards7†
Abstract
Background: At present, there are no prognostic parameters unequivocally predicting treatment failure in early
rheumatoid arthritis (RA) patients. We investigated whether baseline ultrasonography (US) findings of joints, when
added to baseline clinical, laboratory, and radiographical data, could improve prediction of failure to achieve Disease
Activity Score assessing 28 joints (DAS28) remission (<2.6) at 1 year in newly diagnosed RA patients.
Methods: A multicentre cohort of newly diagnosed RA patients was followed prospectively for 1 year. US of the hands,
wrists, and feet was performed at baseline. Clinical, laboratory, and radiographical parameters were recorded. Primary
analysis was the prediction by logistic regression of the absence of DAS28 remission 12 months after diagnosis and
start of therapy.
Results: Of 194 patients included, 174 were used for the analysis, with complete data available for 159. In a multivariate
model with baseline DAS28 (odds ratio (OR) 1.6, 95% confidence interval (CI) 1.2–2.2), the presence of rheumatoid
factor (OR 2.3, 95% CI 1.1–5.1), and type of monitoring strategy (OR 0.2, 95% CI 0.05–0.85), the addition of baseline US
results for joints (OR 0.96, 95% CI 0.89–1.04) did not significantly improve the prediction of failure to achieve DAS28
remission (likelihood ratio test, 1.04; p = 0.31).
Conclusion: In an early RA population, adding baseline ultrasonography of the hands, wrists, and feet to commonly
available baseline characteristics did not improve prediction of failure to achieve DAS28 remission at 12 months.
Trial registration: Clinicaltrials.gov, NCT01752309. Registered on 19 December 2012.
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Background
The prognosis of patients with rheumatoid arthritis (RA)
has improved considerably over the past decades, with
early intensive treatment with conventional synthetic
and biological disease-modifying anti-rheumatic drugs
(DMARDs) [1, 2]. Early intensive treatment nowadays is
according to ‘treat to target’ [3] and ‘tight control’
paradigms and strategies [4–6]. This has been shown to
beneficially alter the long-term outcome of RA patients,
especially if applying these strategies early and within
the so-called ‘window of opportunity’ [7–11].
Personalised medicine in a ‘treat to target’ and ‘tight
control’ setting in RA would require precise and valid
instruments predicting which treatment strategy is ne-
cessary to achieve the treatment target. These instru-
ments would enable us to decide which patients need
more intensive therapy at the initiation of such therapy.
Some patients failing to achieve the treatment target of
‘low-disease activity’ (LDA) or remission would have
benefitted from combination therapy from the moment
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of diagnosis, while monotherapy with methotrexate suf-
fices in others. Not many indisputable prognostic
parameters in RA patients exist [12]. The parameters
most unequivocally predicting a less favourable outcome
of RA are high baseline disease activity [13], rheumatoid
factor (RF) positivity [14], and peri-articular bone
oedema on magnetic resonance imaging (MRI) [15]
Arthritis assessed at ultrasonography (US) at baseline
might also have predictive abilities since US has been
shown to predict progression to RA in undifferentiated
arthritis [16, 17]. Furthermore, in RA patients in remis-
sion, US results predict the occurrence of flare and
erosive progression [18–21]. Based on these results, it
has been suggested that we should include joint US find-
ings in remission criteria for RA [22, 23], or to use US
for classification criteria of RA [24].
A recent study investigating US predictors for clinical
remission did not show US to be predictive for clinical
remission. However, in this study there was a more than
50% dropout rate, with significant differences between
the tender joint count (TJC) and swollen joint count
(SJC) of dropouts and patients included in the final ana-
lysis [25]. Thus, in a newly diagnosed RA population
starting treatment, it remains equivocal whether baseline
US results can help to predict clinical outcomes, as
assessed by the Disease Activity Score assessing 28 joints
(DAS28) [26–28].
The aim of this study was to see whether a more indi-
vidualised therapy from the start might be possible in
newly diagnosed RA patients who will be treated to tar-
get; this is achieved by investigating whether failure to
achieve DAS28 remission after 1 year is associated with
baseline joint US arthritis findings when added to base-
line clinical, laboratory, and radiographical predictors.
Secondary aims include associations of joint US arthritis
findings with the absence of the EULAR good response
criterion after 1 year of therapy and with progression of
radiographical joint damage. Additionally, we investi-
gated the association between US joint inflammation at
baseline and after 1 year.
Methods
This was a multicentre (n = 7) Dutch study prospectively
following for 1 year a cohort of consecutively recruited,
newly diagnosed RA patients (1987 ACR criteria) [29],
consisting of four sub-cohorts of which two were on-
going clinical trials: the tREACH (Treatment in the
Rotterdam Early Arthritis Cohort), with monitoring
every 3 months and treatment escalation if the target of
low disease activity was not met [30]; and the U-Act-
Early trial [31], with monitoring every 4 weeks and treat-
ment escalation as long as remission was not achieved.
The third sub-cohort from which patients were included
was the “Reumatologie Online Monitoring Applicatie”
(ROMA), with monitoring intervals varying from 4 to 12
weeks and treatment escalation according to protocol, as
long as remission was not achieved [32]. The fourth sub-
cohort consisted of early RA patients from the other
centres with monitoring at least every 3 months and
treatment escalation according to treat to target, at the
discretion of the physician, but following the tREACH
protocol (cohort one) as closely as possible. Thus, all pa-
tients were treated according to a step-up ‘tight control’
and ‘treat to target’ strategy; treating physicians were
blinded to results of US examination. Symptom duration
was less than 1 year, and all patients were naive for treat-
ment with DMARDs, including biologicals or glucocorti-
coids. Treatment strategies included at least a potent
conventional synthetic DMARD, such as methotrexate
and/or a biological DMARD, with or without glucocorti-
coids. Prednisolone monotherapy was accepted in nine
patients. Exclusion criteria were contraindications for
conventional synthetic DMARDs, biological therapy, or
glucocorticoids, and illiteracy and personality disorders
limiting participation in the study. Patients underwent
clinical, laboratory, radiographical, and US joint examin-
ation at study enrolment (baseline) and at 1-year follow-
up. The study was approved of by the medical ethical
committee of the Erasmus MC in Rotterdam. All patients
signed a consent form prior to inclusion in the study.
Clinical, laboratory, and radiographical assessment
Demographics were recorded for each patient. At base-
line and at 1 year joint counts included in DAS [33], as
well as the patients’ overall assessment of disease activity
using a visual analogue scale (VAS), were scored. Func-
tional ability was evaluated using the Dutch Health
Assessment Questionnaire (DHAQ) [34] (https://www.
nvr.nl/wp-content/uploads/2014/11/NL_consensus_HAQ.p
df), with higher DHAQ scores indicating more disability.
C-reactive protein (CRP) and erythrocyte sedimenta-
tion rate (ESR) were obtained at both visits; RF and anti-
cyclic citrullinated peptide (aCCP) status were recorded
at baseline only. Manufacturer’s cut-off values were used
for analyses.
The Sharp-van der Heijde (SvH) scoring method was
used to assess radiographic progression of the joints of
hands and feet. Anonymised radiographs were read in
chronological order [35] by two readers; agreement
between them was calculated with intraclass correlation
coefficient ICC(A,1). The SvH score consists of the ero-
sion score (0–280) and joint space narrowing (JSN)
score (0–168) of hands, wrists, and feet, leading to a
maximal score of 448. Progression was defined as a
change over time greater than the smallest real differ-
ence (SRD), which was derived from the agreement
analysis (ICC) between the two readers [36].
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US assessment
For the US examination, each centre used a Esaote
MyLab60 machine with a LA-435 probe (linear array
6–18 MHz). The second to fifth metacarpophalangeal
(MCP) and proximal interphalangeal (PIP) joints of both
hands were scanned in the dorsal and palmar orienta-
tion. Bilaterally, radiocarpal, intercarpal, and second to
fifth metatarsophalangeal (MTP) joints were scanned
dorsally. The ulnocarpal joint was not included because
it was found to be the least reliable orientation in which
to scan the wrist [37]. Patient and probe positioning
were according to EULAR guidelines [38], with the
probe position on the wrist specified in more detail (see
Fig. 1). Greyscale US (GSUS) and power Doppler US
(PDUS) were performed. The GSUS scoring system for
synovitis was semiquantitative (0–3), with ‘0’ indicating
no US signs of inflammation and ‘3’ indicating severe
inflammation, using Naredo’s modification of the scoring
system of Szkudlarek and colleague [39], combining the
criteria for joint effusion and synovial proliferation. For
erosions, the binary scoring system presented by
Wakefield and colleagues [40] was modified to a semi-
quantitative (0–3) scoring system, assigning higher
scores to larger erosions. PDUS scores were according
to the semiquantitative (0–3) PD scoring system of
Szkudlarek and colleagues [39].
For PDUS, the colour gain was set at the disappear-
ance of colour noise, frequency at 10 MHz, a pulse repe-
tition frequency (PRF) of 750 Hz and wall filter (WF) at
level 3 out of 5. We adjusted the size and position of the
colour box to include the subcutaneous tissue to
recognize artefacts caused by vessels above the joint.
Based on data in the literature, we considered a joint to
be inflamed if it was scored with at least a grade 2 in the
GSUS domain and/or at least a grade 1 in the PDUS
domain, which resulted in a US joint count (USJC; score
0–28) per patient [41, 42]. For explorative purposes, we
investigated different US cut-offs for arthritis in individ-
ual joints (e.g. GSUS > 2 and PD > 1) to produce differ-
ent US sum scores for individual patients.
All seven ultrasonographers, blinded to clinical find-
ings, had been certified for US by the Dutch College of
Rheumatology. Prior to the start of the study we orga-
nized meetings with all ultrasonographers to discuss the
scoring of static images using the scoring systems men-
tioned above. From these meetings a consensus was
reached on how to score images. With this consensus
we then composed an atlas with sample images and
cartoons for each grade of GSUS, PDUS, and erosive
changes. This was distributed to all ultrasonographers,
and four training sessions prior to and five more during
the study were organized to optimise both interpretation
and acquisition reliability between ultrasonographers
using this atlas [43].
Statistical analysis
In our protocol the number of patients with a
DAS44 > 3.4 1 year after diagnosis had been chosen
as the primary outcome. However, actual data showed
that only 10 cases met this criterion. Therefore, we
redefined our primary outcome by the absence of DAS28
remission (i.e. DAS28 ≥ 2.6) at 1 year of therapy. Clinical,
laboratory, radiographical, US sum scores, and US cut-offs
were investigated for association with the absence of
DAS28 remission (DAS28 ≥ 2.6) at 1 year using a logistic
regression of complete cases. Parameters that were uni-
variately associated with a p value < 0.2, or had shown to
have prognostic value in the literature, were included in
the multivariate model, which was reduced by backward
selection (p < 0.05). The analyses were repeated after
multiple imputation (10 datasets) (results are presented in
Additional file 1).
Secondary outcomes were ‘absence of EULAR good
response’, analysed with the same analysis as for the
primary outcome. Also, ‘presence of radiographical
progression’ as assessed by progression on the SvH score
greater than the SRD was analysed using a Mann-
Whitney U test. Additionally, we investigated the associ-
ation of the extent of inflammation at US at baseline
with that at 1-year follow-up. The cross-sectional associ-
ations of US arthritis scores and DAS28 were also
evaluated at baseline and 1 year using a Spearman
correlation coefficient.
In addition, several US sum scores and US cut-offs
were tested in multivariate analyses, while keeping the
other variables constant. A value of p < 0.05 was
Fig. 1 Probe position for scanning the wrist. Bottom two red crosses
represent Lister’s tubercle (radial) and the ulnoradial joint (ulnar). The
top red cross represents the base of the third digit. Green line shows
probe position
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considered to be statistically significant; all tests were
two-sided, and STATA 12, (StataCorp, Texas, USA) was
used to analyse the data.
Results
Patients
Out of the 174 patients, 159 patients had complete
follow-up data (91%); 14 patients dropped out, and
for one patient we could not calculate the primary
outcome. No significant differences in baseline char-
acteristics were observed between complete (n = 159)
and incomplete (n = 15) cases.
Of the 174 participating patients, 64% were female; the
mean (standard deviation (SD)) age was 54.8 (14) years,
the median (interquartile range (IQR)) symptom dur-
ation was 4.6 (2.8–7.9) months; baseline mean (SD)
DAS28 was 4.9 (1.3); 67% of patients were RF positive
and 60% were aCCP positive, and 24% of patients had
erosions (SvH erosion score > 1) at baseline (Table 1). At
12 months, the mean (SD) DAS28 was 3.5 (0.9) with a
median (IQR) of 1 (0–3) swollen joints and 3 (0–5)
tender joints; 38% of the patients failed to achieve
DAS28 remission and 30% did not achieve the EULAR
good response criterion while 3.3% progressed radio-
graphically more than the SRD (6.4 SvH units).
US findings
At baseline (n = 174) the median (IQR) joint count per
patient regarding synovitis at US (USJC) was 5 (2–9); for
erosions at US it was 0 (0–1). The joints most com-
monly inflamed (GSUS > 1 and/or PDUS > 0) at baseline
were radiocarpal joints (right 44%, left 41%), the left
MTP2 (36%), and the left MCP2 on the palmar side (35%).
Erosions at US were mainly seen in both MTP5 joints
(right 23%, left 22%). On x-ray, erosions were seen in 8%
and 15% of these respective joints. At 1 year (n = 159),
median (IQR) USJC score was 0 (0–3) and for US erosions
it was 0 (0–1). The most frequently inflamed joints at 1
year were radiocarpal joints (right 14%, left 15%) and the
right MCP2 joint (14%). Erosions were found most fre-
quently in MTP5 joints (right 21%, left 25%). On x-ray,
erosions were seen in 15% and 21% of these respective
joints. Of the 159 patients for whom 1-year US examin-
ation was available, 16 patients (10%) did not have inflam-
mation at US at baseline, and 13 (81%) of those also did
not have inflammation at US at 1-year follow-up.
We found no cross-sectional association between US
inflammation and DAS28 or the individual DAS28
components at baseline or after 1 year. At baseline, the
Spearman correlation coefficient for US inflammation score
and DAS28 = 0.26, for SJC28 = 0.22, for TJC28 = 0.04, for
ESR = 0.24, and for the VAS = 0.12 (all p > 0.05). At 1 year,
these were similar.
Reliability of US data
After four training sessions prior to the start of our
study, interobserver reliability (ICC(A,1)) at the joint
level between the seven ultrasonographers was 0.58
(95% confidence interval (CI) 0.45–0.72) for GSUS, and
0.48 (0.34–0.64) for PDUS, while it was s 0.58
(0.49–0.68) for the two modalities combined. However,
the percentage exact agreement at the patient level (i.e.
the agreement of ultrasonographers for classifying a
patient as having arthritis or not) was 95%.
Factors associated with failure of DAS28 remission
Sixty-one patients (38%) failed to achieve DAS28 remis-
sion at 12 months. This was associated in the univariate
analysis with a higher DAS28 score and higher ESR at
baseline (p < 0.05). Neither the USJC (GSUS > 1 and/or
PDUS > 0) nor US erosion score were associated.
Categorizing patients into quartiles based on baseline
USJC did not yield significant results, nor did using
other definitions of US inflammation. Building a multi-
variate model resulted in a final model with baseline
DAS28, RF, age, and the monitoring strategy with the
shortest assessment interval (i.e. every 4 weeks) (Table 2).
Adding US results to the final model did not significantly
improve the fit of the model (LR Chi2 = 1.04; p = 0.31).
The analysis with imputed data yielded almost equal
results (see Additional file 1).
Effect of different US sum scores and cut-offs on the
multivariate analysis
In our primary analysis, joints were considered to be
inflamed at US if GSUS > 1 and/or PDUS > 0. We also
Table 1 Baseline characteristics of the patients
Age in years, mean (SD) 54.8 (14)
Symptom duration in months (n = 166) 4.6
Gender, % female 64%
DAS28, mean (SD) 4.9 (1.3)
SJC28 at baseline 6 (3–11)
TJC28 at baseline 6 (2–10)
ESR (n = 173) 27 (12–47)
VAS, mean (SD) 51 (24)
RF, % positive (n = 171) 67%
aCCP, % positive (n = 171) 60%
RF and aCCP, % positive (n = 171) 54%
HAQ (n = 155), 0.88 (0.38–1.25)
USJC 5 (2–9)
n = 174, unless specified otherwise
Median (interquartile range) are presented unless specified otherwise
aCCP anti-cyclic citrullinated peptide, DAS Disease Activity Score, ESR erythrocyte
sedimentation rate, HAQ Health Assessment Questionnaire, RF rheumatoid factor,
SD standard deviation, SJC swollen joint count, TJC tender joint count, USJC
ultrasonographic joint count, VAS visual analogue scale
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evaluated several US sum scores and US cut-offs. No
US sum score or cut-off was univariately significantly
associated with the outcome. The coefficients of the
US parameters did not significantly change either
when testing all US sum scores and US cut-offs in a
multivariate analysis (Table 3).
Secondary outcomes
We evaluated the prediction of not achieving the
EULAR good response criterion, radiological progres-
sion, and presence of inflammation at US at 12
months as secondary outcomes; 30% of patients did
not achieve EULAR good response. Adding US results
to the final model did not significantly improve the
fit of the model (LR Chi2 = 0.98; p = 0.32). Only five
patients showed radiographical progression larger than
the SRD. These patients numerically had a higher
grade of US joint inflammation at baseline compared
to those without radiographical progression: median
(IQR) USJC 8 (7–10) versus USJC 5 (2–9), respect-
ively; this difference did not reach statistical signifi-
cance (p > 0.05). Those with a USJC of 0 at 12
months had a median (IQR) USJC of 4 (1–7) at base-
line, whereas those with USJC > 0 at follow-up had a me-
dian (IQR) USJC of 6 (4–10) at baseline (p = 0.003).
Table 2 Univariate and multivariate association of relevant patient characteristics with the outcome: absence of DAS28 remission
at 12 months
Variable Univariate Multivariate
OR (95% CI) P value OR (95% CI) P value
DAS28 per point 1.34 (1.03–1.73) 0.03 1.60 (1.18–2.2) 0.002
Female gender 1.94 (0.96–3.3.9) 0.06 1.93 (0.91–4) 0.09
RF positive 1.78 (0.87–3.63) 0.11 2.34 (1.07–5.1) 0.03
aCCP positive 1.54 (0.79–3) 0.21
RF and aCCP positive 1.59 (0.83–3) 0.17
Age per year 1.01 (0.99–1.04) 0.24
Monitoring strategy
Sub-cohort A Reference NA Reference NA
Sub-cohort B 0.49 (0.13–1.73) 0.27 0.20 (0.05–0.85) 0.03
Sub-cohort C 1.26 (0.47–3.39) 0.64 0.68 (0.20–2.4) 0.55
Sub-cohort D 1.26 (0.26–1.48) 0.28 0.85 (0.30–2.4) 0.76
Symptom duration (months) 1.0 (0.91–1.1) 0.99
SvH per point 1.04 (0.93–1.15) 0.48
Smoking yes/no 1.56 (0.73–3.4) 0.25
HAQ per point 1.16 (0.71–1.9) 0.55
USJC per point 0.99 (0.92–1.06) 0.77 0.96 (0.89–1.04) 0.31
Absence of remission = 1
Ultrasound joint count (USJC) = number of joints with at least greyscale (GS) > 1 or power Doppler (PD) > 0
Multivariate model including: DAS28 at baseline, RF, monitor strategy, gender, and USJC
Monitor strategies: Sub-cohort A, monitoring at least every 3 months and treatment escalation at the discretion of the physician; sub-cohort B, monitoring every 4
weeks and treatment escalation if no remission; sub-cohort C, monitoring varies between 4 and 12 weeks and treatment escalation if no remission, prespecified in
a protocol [24]; sub-cohort D, monitoring every 3 months and treatment escalation if no low-disease activity [23]
aCCP anti-cyclic citrullinated peptide, CI confidence interval, DAS Disease Activity Score, HAQ Health Assessment Questionnaire, NA not applicable, OR odds ratio, RF rheumatoid
factor, SvH Sharp-van der Heijde
Table 3 Results of logistic regression analyses with different US
definitions predicting the absence of DAS28 remission at 1 year
Ultrasound score OR (95% CI)
Per point of:
GS 0.99 (0.96–1.02)
PD 0.99 (0.95–1.03)
Number of joints with:
GS > 1 0.67 (0.27–1.71)
PD > 0 0.80 (0.30–2.16)
GS > 1 and/or PD > 0 0.96 (0.89–1.04)
GS > 1 or PD > 0 0.96 (0.42–2.23)
GS > 2 0.56 (0.27–1.20)
GS > 2 or PD > 0 0.57 (0.27–1.21)
GS > 0 and PD > 1 0.82 (0.39–1.7)
GS > 0 and PD > 2 1.12 (0.41–3.01)
GS > 1 and PD > 2 1.12 (0.41–3.01)
GS > 2 and PD > 1 0.71 (0.32–1.56)
GS > 2 and PD > 2 1.26 (0.37–4.24)
GS > 0 or PD > 0 0.40 (0.12–1.33)
Continuous measures: ultrasound joint count = number of joints with greyscale
(GS) > 1 and/or power Doppler (PD) > 0; GS sum= sum of GS scores; PD sum= sum
of PD scores; GS > x, presence of a joint(s) with a GS> x; PD > y, presence of a joint
with a PD > y
CI confidence interval, OR odds ratio
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Discussion
Results of routinely performed US at baseline show no
additional prognostic information when added to clin-
ical, laboratory, and radiographical parameters in pre-
dicting failure to achieve DAS28 remission at 1 year in
early RA patients treated to target. The absence of re-
mission was associated with high DAS28 at the time of
diagnosis and RF positivity, confirming data in the litera-
ture [12–14]. The monitoring strategy with the shortest
assessment interval (4-week visits), corrected for DAS28
and RF positivity at baseline, appeared to increase the
chance to achieve remission.
The absence of a predictive value of US in this
study contrasts with data showing that US predicts
patients with undifferentiated arthritis (UA) progres-
sing to RA [16, 17] and RA patients in remission
progressing to flare and erosion [18–21]. Our negative
study results may be explained by the earlier observa-
tion that intensive therapy diminishes the prognostic
value of baseline conventional prognostic factors [8].
Our negative results are in line with earlier
observations in a smaller population of RA patients
not treated to target, 64% of whom received glucocor-
ticoids prior to inclusion in the study [26]. However,
in that study ‘time integrated values’ of PDUS
correlated with clinical outcomes, which was not
found in our study.
It has been suggested that one of the most important
steps we have yet to take in US research in RA is to in-
vestigate the added value of US and clinical indices in
multicentre trials for clinical and radiological out-
comes of RA patients [44]. Our study has done this.
Although our study has shown that the added predict-
ive value of routinely performed US at baseline in early
RA patients is absent if treated to target, US still has a
place in personalised medicine for specific indications.
For example, in patients for whom the widely used
DAS28 is less valid, e.g. patients with concomitant
fibromyalgia who will have a high tender joint count
and high VAS, and also for obese patients in whom the
clinical joint examination may be difficult and who
may have a higher ESR without joint inflammation
[45]. In these patients, US may really make a clinically
relevant contribution. US might help to distinguish pa-
tients with or without joint inflammation making more
personalised medicine possible. To that aim, new trials
should be performed using US measures as target for
treatment, or using US as a basis for treatment escal-
ation and tapering; initiatives using US as an outcome
measure have been published [46, 47]. In our opinion,
the observation that more than 80% of the patients
who did not have US inflammation at baseline also did
not have US inflammation at follow-up deserves fur-
ther investigation.
A limitation of our study was heterogeneity in the
strategies and assessment intervals of the sub-cohorts
from which we included patients. All patients, how-
ever, were treated according to a ‘treat to target’ and
‘tight control’ strategy’. Our patients had relative mild
disease with a median six swollen joints at baseline;
however, this reflects an early RA population and
application of the more sensitive, newest RA classifi-
cation criteria [24]. Both are aspects of normal daily
clinical practice in which future US trials as suggested
above should also be performed [44]. Another limita-
tion may be the use of US equipment that now might
be seen as midrange and less sensitive compared to
current high-end machines. However, this also reflects
routine practice. More importantly, however, the PD
modality in the machines used is actually very sensi-
tive, even better than that of professional research
machines [48]. Another possible limitation of our
study is that we did not scan all joints included in
the DAS28; it could be argued that we missed US in-
flammation. However, more than 90% of the patients
in our study had US inflammation at baseline, and
US scoring of a limited sets of joints also well reflects
RA activity [49, 50]. A last issue of critical discussion
is the moderate agreement coefficients between ultra-
sonographers, despite organizing several trainings ses-
sions to increase reliability. Generally, reliability in
ultrasound is not a bigger problem than in other im-
aging modalities if performed by trained examiners
[51], as was the case in our study. That the agree-
ment coefficients are moderate is probably largely at-
tributable to relatively low levels of detectable
inflammation at US in the patients participating in
the trainings sessions; ICC values are low in samples
with a homogeneous distribution, i.e. with only very
high or very low scores of arthritis. Since the hetero-
geneity of the scores in the patient population largely
determines the value of reliability measures [43], we
tried to select joints from the patients for the training
sessions with scores ranging from 0 to 3. Apparently,
we did not succeed in doing this well enough. The
hypothesis that the reliability coefficients in our study
underestimate reliability is corroborated by the obser-
vation that the percentage exact agreement at the pa-
tient level was 95%.
Conclusion
In conclusion, in an early RA population, treated accord-
ing to the ‘treat to target’ paradigm, adding data from
US of the joints at baseline to the work-up did not
improve prediction for not achieving DAS28 remission
or EULAR good response, nor the prediction of radio-
graphical progression at 1 year.
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